Castle Biosciences CSTL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$14.52M+43.8% | -$2.33M-124% | -$501K-122% | $4.52M-49.3% | -$25.85M-920% | ||
| $3.93M-86.8% | $3.78M-34.5% | $3.82M+7.8% | $3.41M+2.0% | $29.76M+791% | ||
| $9.78M-12.6% | $11.41M-0.3% | $12.1M-7.1% | $11.21M-15.0% | $11.18M-11.8% | ||
| -$10K+98.7% | -$907K— | $0-100% | -$4.67M-203% | -$770K— | ||
| -$1.08M-121% | -$6.27M-916% | -$1.91M-145% | -$3.91M-216% | $5.22M+22.4% | ||
| $207K+116% | $1.6M+2.6% | $307K+121% | $1.52M+312% | -$1.29M-333% | ||
| $3.19M+419% | $0+100% | $1.41M+165% | $1.07M+187% | $615K+246% | ||
| -$19.18M-30.5% | $6.52M+33.6% | —— | —— | -$14.7M-3.2% | ||
| $6.67M+98.2% | —— | —— | $1.33M+597% | $3.36M+3,166% | ||
| -$532K-1,673% | —— | -$63K+49.6% | -$189K— | -$30K+83.2% | ||
| $2.02M+242% | —— | $3.56M— | $1.19M— | -$1.43M— | ||
| -$172K+67.3% | -$209K+50.9% | -$197K+54.3% | -$343K-88.5% | -$526K-110% | ||
| -$22.13M-267% | $26.93M+10.5% | $22.63M-3.0% | $20.82M-13.2% | -$6.04M+11.7% | ||
| $12.46M+163% | $7.18M-5.1% | $14.83M+133% | $9.26M+77.1% | $4.74M-48.2% | ||
| $55.14M+13.8% | $37.41M-20.9% | $58.47M+29.3% | $44.4M-15.3% | $48.43M-20.3% | ||
| $2.68M— | —— | —— | —— | $0— | ||
| $7K-22.2% | $5K-28.6% | $19K+375% | $12K+500% | $9K+80.0% | ||
| $0-100% | —— | —— | —— | $5.57M— | ||
| —— | $528.5K— | $528.5K— | $528.5K— | $528.5K— | ||
| -$25.8M-15.0% | —— | -$18.39M-24.3% | -$28.38M-32.5% | -$22.43M-13.9% | ||
| $322K+1,689% | $2.09M+461% | $77K-95.1% | $19K+138% | $18K-72.3% | ||
| $24K-7.7% | $27K+3.8% | $31K+29.2% | $31K+182% | $26K-27.8% | ||
| $6.6M+162% | $7.37M+15.5% | $1.19M-8.4% | $589K-4.2% | $2.52M+431% | ||
| -$5.03M-224% | -$4.59M— | -$919K-210% | $0-100% | -$1.55M-115% | ||
| -$52.97M-76.4% | —— | —— | -$7.46M— | -$30.02M-88.9% | ||
| $454K-68.4% | $708K-56.1% | $905K-45.2% | $1.17M-32.0% | $1.44M-15.5% | ||
| $2.02M+242% | —— | —— | —— | -$1.43M-1,127% | ||
| -$19.18M-30.5% | $6.52M+33.6% | —— | —— | -$14.7M-3.2% | ||
| -$172K+67.3% | -$209K+50.9% | -$197K+54.3% | -$343K-88.5% | -$526K-110% | ||
| -$371K+11.7% | -$356K-11.3% | -$352K-8.6% | -$244K+28.2% | -$420K-24.3% | ||
| $2.76M+141% | —— | $1.43M+46.0% | —— | $1.14M+1,463% | ||
| $530K+1,295% | $312K+205% | $41K-77.0% | $0+100% | $38K-83.5% | ||
| $6.67M+98.2% | —— | —— | $1.33M+597% | $3.36M+3,166% | ||
| -$532K-1,673% | —— | -$63K+49.6% | -$189K— | -$30K+83.2% | ||
| $0-100% | —— | —— | —— | $5.57M— | ||
| $2.68M— | —— | —— | —— | $0— | ||
| $7K-22.2% | $5K-28.6% | $19K+375% | $12K+500% | $9K+80.0% | ||
| $24K-7.7% | $27K+3.8% | $31K+29.2% | $31K+182% | $26K-27.8% | ||
| $1.27M+30.6% | $714K+10.4% | $220K-62.4% | $512K-22.4% | $970K-10.9% | ||
| $4.1M+27.4% | $6.89M+943% | —— | $3.61M+149% | $3.22M+360% | ||
| -$172K+67.3% | -$209K+50.9% | -$197K+54.3% | -$343K-88.5% | -$526K-110% | ||
| $0-100% | —— | —— | $75K-54.8% | $44K— | ||
| -$34.58M-221% | $19.75M+17.6% | $7.8M-54.0% | $11.56M-38.4% | -$10.78M+32.6% | ||
| -$34.58M-221% | $19.75M+17.6% | $7.8M-54.0% | $11.56M-38.4% | -$10.78M+32.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Castle Biosciences generate?
- Castle Biosciences (CSTL) generated $48.3M in operating cash flow over the trailing twelve months.
- What is Castle Biosciences's free cash flow?
- After $43.7M of capital expenditures, Castle Biosciences's free cash flow was $4.5M over the trailing twelve months, down 89.2% year over year.
- Where does Castle Biosciences's cash flow data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
